Chen TT, Lv JJ, Chen L, Li M, Liu LP. Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis. World J Gastroenterol 2023; 29(35): 5154-5165 [PMID: 37744293 DOI: 10.3748/wjg.v29.i35.5154]
Corresponding Author of This Article
Li-Ping Liu, MD, PhD, Doctor, Department of Emergency Critical Care Medicine, The First Hospital of Lanzhou University, No. 1 West Road, Donggang, Chengguan District, Lanzhou 730000, Gansu Province, China. liulipingldyy@126.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Chen TT, Lv JJ, Chen L, Li M, Liu LP. Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis. World J Gastroenterol 2023; 29(35): 5154-5165 [PMID: 37744293 DOI: 10.3748/wjg.v29.i35.5154]
World J Gastroenterol. Sep 21, 2023; 29(35): 5154-5165 Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5154
Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis
Li-Ping Liu, Min Li, Ling Chen, Jia-Jun Lv, Ting-Ting Chen
Ting-Ting Chen, Jia-Jun Lv, The First Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730000, Gansu Province, China
Ling Chen, Min Li, Li-Ping Liu, Department of Emergency Critical Care Medicine, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
Author contributions: Chen TT collected the clinical data for data analysis and mapping and drafted the manuscript; Lv JJ collected the blood samples from the patients and performed the flow cytometry; Chen L collected blood from the patients and completed the enzyme-linked immunosorbent assays; Li M screened the research subjects and carried out clinical interventions; Liu LP participated in the experimental design, supervised the experimental process and reviewed the experimental results; and all the authors have read and approved the final manuscript.
Supported bythe Science and Technology Department of Gansu Province, No. 20JR5RA35; Science and Technology Project of Gansu Province, No. 22JR10KA009; Talent Innovation and Entrepreneurship Project of Science and Technology Bureau of Chengguan District, Lanzhou, No. 2020RCCX0030; and Lanzhou Science and Technology Development Guiding Plan Project, No. 2019-ZD-37.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Clinical Research (drugs, devices) of The First Hospital of Lanzhou University.
Clinical trial registration statement: This study is registered at Chinese Clinical Trial Registry (https://www.chictr.org.cn/). The registration identification number is ChiCTR2300072241.
Informed consent statement: All study participants or their legal guardians agreed to be enrolled in the study and provided consent (written or oral).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: This study is registered at Chinese Clinical Trial Registry (https://www.chictr.org.cn/), and the data is shared on this platform.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Corresponding author: Li-Ping Liu, MD, PhD, Doctor, Department of Emergency Critical Care Medicine, The First Hospital of Lanzhou University, No. 1 West Road, Donggang, Chengguan District, Lanzhou 730000, Gansu Province, China. liulipingldyy@126.com
Received: July 5, 2023 Peer-review started: July 5, 2023 First decision: August 10, 2023 Revised: August 23, 2023 Accepted: September 5, 2023 Article in press: September 5, 2023 Published online: September 21, 2023 Processing time: 71 Days and 9.3 Hours
ARTICLE HIGHLIGHTS
Research background
Patients with sepsis are at high risk for acute gastrointestinal injury (AGI), heparanase (HPA) plays an important role in septic AGI (S-AGI), but its specific mechanism is not completely understood, and few clinical reports are available.
Research motivation
This study is to explore the effect and mechanism of HPA inhibition in S-AGI patients.
Research objectives
To prove the role of HPA in S-AGI and search for effective biomarkers and therapeutic targets for the diagnosis of S-AGI.
Research methods
The therapeutic effect of S-AGI patients in control group and low molecular weight heparin group was compared by a prospective double-blind randomized controlled trial. To evaluate the feasibility of HPA as a diagnostic biomarker for S-AGI.
Research results
HPA inhibitors can significantly improve AGI score, gastrointestinal function, coagulation function and immune function in S-AGI patients. The inhibitory effect of HPA in gastrointestinal protection may be achieved by enhanced autophagy.
Research conclusions
HPA has great potential as a diagnostic marker for S-AGI. Inhibition of HPA activity reduces syndecan-1 shedding and alleviates S-AGI symptoms. The inhibitory effect of HPA in gastrointestinal protection may be achieved by enhanced autophagy.
Research perspectives
HPA has great potential as a diagnostic biomarker for S-AGI, and its inhibitor is a good therapeutic drug choice in clinical practice.
